Focused On-demand Library for Bromodomain testis-specific protein

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q58F21

UPID:
BRDT_HUMAN

ALTERNATIVE NAMES:
Cancer/testis antigen 9; RING3-like protein

ALTERNATIVE UPACC:
Q58F21; A6NF68; B7Z811; B7Z890; B7ZAX7; D3DT32; O14789; Q05DQ4; Q6P5T1; Q7Z4A6; Q8IWI6

BACKGROUND:
The Bromodomain testis-specific protein, identified as Cancer/testis antigen 9 and RING3-like protein, is integral to spermatogenesis. It binds acetylated histones H4K5ac and H4K8ac, crucial for gene activation in meiotic and post-meiotic cells. Its role extends to the removal of hyperacetylated histones post-meiosis and involvement in mRNA splicing and 3'-UTR truncation, highlighting its multifaceted function in sperm development.

THERAPEUTIC SIGNIFICANCE:
The direct association of Bromodomain testis-specific protein with Spermatogenic failure 21, an infertility disorder, underscores its therapeutic potential. Exploring this protein's functions could lead to innovative treatments for infertility issues stemming from spermatogenesis impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7555 of 8789